The expansion of production facilities by market players is anticipated to fuel the growth of the worldwide ribonucleic acid (RNA) markers market throughout the course of the projected period. For instance, as part of a 10-year cooperation with the Canadian government and in order to improve the firm's pandemic response, Moderna, Inc., a pharmaceutical and biotechnology corporation with headquarters in the United States, plans to increase its manufacturing capacity in Canada on January 20, 2023. Additionally, for the same reason as stated above, the company plans to increase the size of its manufacturing site in Australia. The business also intends to increase the size of its Kenyan manufacturing facility. It is anticipated that the Australian plant will yearly generate up to 100 million doses of mRNA vaccines, including those for respiratory illnesses.
In-depth analysis of the global Ribonucleic Acid (RNA) Markers Market is provided in this study, along with market size (US$ Million) and compound annual growth rate (CAGR%) projections for the years 2023 through 2030, with 2022 serving as the base year.
Major Players in the Ribonucleic Industry:
1. Agilent Technologies, Inc.: Established in 1999. Headquarters are in the United States. Agilent, which was split off from Hewlett-Packard in 1999, has grown into a premier life sciences and diagnostics company. Agilent's measuring technologies now serve a diverse range of clients through its three operating segments: life science and applied tools, cross lab (consisting of life science and applied tools consumables and services), and diagnostics and genomics. Agilent Purchases Artificial Intelligence Technology to Increase Lab Productivity.
2. PerkinElmer Inc.: It was founded in 1931. Headquarters are in the United States. Revvity supplies pharmaceutical, biomedical, chemical, environmental, and general industrial markets with instruments, tests, services, and software solutions. The company is divided into two segments. The first segment is diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions include applications in life science, industrial, environmental, and food science. Revvity provides a wide range of goods and services, including genetic screening and environmental analytical tools, as well as informatics and enterprise software. SonoVol (Feb 2022), BioLegend (Jul 2021), and Sirion Biotech (Jun 2021) are the most recent acquisitions.
3. F. Hoffmann-La Roche Ltd: Established on October 1st, 1896. Headquarters in the United States. Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar.
4. Merck KGaA: .: Established in 1891. German headquarters are in Darmstadt. The three primary business sectors of Merck KGaA are life sciences, performance materials, and healthcare. Researchers in academia and applied disciplines, such as the biopharmaceutical industry, are principally served by the life sciences segment (47% of 2022 sales), which also offers laboratory supplies and services. Merck discovers, produces, and distributes branded drugs with major therapeutic concentrations in oncology, multiple sclerosis, and fertility in the healthcare industry (35%). The business provides speciality materials to make a range of goods, including semiconductors, flat-screen televisions, cars, and cosmetics, under its electronics section (18%). The E. Merck KG family publicly sold a portion of the business in 1995, which led to the current 30% public ownership of the business.
5. Thermo Fisher Scientific Inc.: Established in 1956. Headquarters in the United States. Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. As of mid-2023, the company works through four segments: analytical technologies (16% of sales); speciality diagnostic products (10% of revenue); life science solutions (24% of revenue); and lab goods and services, which includes CRO services (54% of revenue).
6. QIAGEN: Established in 1984. Headquarters are located in Hilden, Germany. Qiagen provides proprietary sample and assay technologies for the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The sales of the company are roughly evenly split between applications in life sciences and molecular diagnostics. Qiagen's revenue is almost entirely comprised of consumables, with the remainder coming from instruments and related services. The Americas generate the most revenue for the company (45% of 2021 sales), followed by EMEA (36%), and Asia-Pacific (19%).
7. Bio-Rad Laboratories, Inc.: Built in 1952. With its headquarters in Hercules, California, Bio-Rad Laboratories creates, produces, and sells goods and services for the clinical diagnostics and life sciences industries. Bio-Rad produces, markets, and maintains test systems and specialised quality controls for clinical laboratories in the diagnostics sector (53% of revenue). The company creates and produces a variety of tools and reagents for use in research, the production of biopharmaceuticals, and food testing in the life sciences sector (47% of revenue). Major markets for the corporation are found in the Americas, Europe, Africa, and Asia-Pacific. Sartorius AG, a supplier of lab supplies and biopharmaceuticals, is 37% owned by Bio-Rad. Acquisition of Curiosity Diagnostics by Bio-Rad.
8. CardioNet: Established in 1999. Headquarters in the United States. Information service provider offering helpful resources for ambulatory cardiac monitoring to medical doctors and other professionals. The company specialises in compiling all ambulatory cardiac monitoring technologies, clinical advancements, and useful industry insights. As a result, doctors and other medical professionals can access all the information they need in one location rather than all over the internet, which will aid in the diagnosis and management of cardiac arrhythmias.
*Definition: The RNA Markers consist of a ladder of nine RNA transcripts that are synthesized in vitro from specific templates.
